Long-term follow-up and salvage surgery in patients with T2N0M0 squamous cell carcinoma of the glottic larynx who received concurrent chemoradiation therapy with carboplatin (CBDCA) – AUC 1.5 vs AUC 2.0

Abstract

The AUC 1.5 combination group showed overall response, CR, 5-year survival, 10-year survival, 5-year larynx preservation, and 10-year larynx preservation rates of 100.0%, 68.0%, 83.4%, 77.0%, 75.2%, and 75.2%, respectively. The AUC 2.0 combination group showed corresponding rates of 100%, 96.0%, 95.7%, 91.1%, 82.9%, and 72.7%, respectively. The most common side effects of grade 3 or more were leukopenia, neutropenia, and mucositis (stomatitis), and all were reversible. Thirteen patients (52.0%) in the AUC 1.5 combination group and nine patients (36.0%) in the AUC 2.0 combination group required salvage surgery. Histologically, concurrent chemoradiation therapy with carboplatin caused more severe cancer tissue degeneration. Pathological examinations indicated that the safety margin for partial laryngectomy was 4 mm from the gross tumor.

Survival and Prognostic Factors for Outcome after Radiotherapy for T2 Glottic Carcinoma

“…This study showed five-year LC rates comparable to those reported in the literature. Our five-year OS and DSS rates were also comparable to those in the literature (ranges 53–91% and 69–100%, respectively) [12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28].…”

The role of changes in maximum standardized uptake value of FDG PET-CT for post-treatment surveillance in patients with head and neck squamous cell carcinoma treated with chemoradiotherapy: preliminary findings

“…However, during the past two decades, organ preservation strategies using chemoradiotherapy (CRT) have become an important treatment approach for locally advanced HNSCC, and these non-surgical approaches have been shown to produce an excellent response at the primary tumour site and at cervical lymph nodes, resulting in high rates of locoregional control. 1 However, CRT does not always provide satisfactory treatment responses and clinical outcomes, even though the clinical staging and treatment method are the same as in the study of Furusaka et al 2 Moreover, residual recurrent tumour occurs in as many as 30-40% of cases, 3 and approximately 80% of tumour recurrences occur during the first 2 years after treatment. 4 The guidelines of the National Comprehensive Cancer Network recommend clinical surveillance with history and physical examinations every 1-3 months during the first year after the treatment of patients with HNSCC, tapering to every 6-12 months after 5 years.…”

A new combined therapy for functional organ preservation and survival in lateral oropharyngeal wall cancer

“…We also reported that concurrent chemoradiation therapy (CCRT) for laryngeal cancer was effective for organ preservation, but not useful for improving the survival rate [2,3]. However, CCRT in combination with docetaxel (DOC) improved both functional laryngeal preservation and overall survival [4].…”